Browse > Article

A Case of Imatinib-mesylate associated Hypersensitivity Pneumonitis  

Lee, Jae Wong (Department of Internal Medicine, College of Medicine, Yeungnam University)
Kim, Hye Jin (Department of Internal Medicine, College of Medicine, Yeungnam University)
Kim, Kyu Jin (Department of Internal Medicine, College of Medicine, Yeungnam University)
Shin, Kyeong Cheol (Department of Internal Medicine, College of Medicine, Yeungnam University)
Hong, Yeong Hoon (Department of Internal Medicine, College of Medicine, Yeungnam University)
Chung, Jin Hong (Department of Internal Medicine, College of Medicine, Yeungnam University)
Lee, Kwan Ho (Department of Internal Medicine, College of Medicine, Yeungnam University)
Publication Information
Tuberculosis and Respiratory Diseases / v.59, no.4, 2005 , pp. 423-426 More about this Journal
Abstract
Imatinib-mesylate (Gleevec, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib is also used to treat patients with c-kit (CD 117)-positive unresectable tumors, or metastatic malignant gastrointestinal stromal tumors, or both. Imatinib is a welltolerated drug with few side effects. However, it has been associated with gastrointestinal irritation, fluid retention and edema, skin rashes, depigmentation, hepatotoxicity, hemorrhage, and hematological toxicity (anemia, neutropenia, and thrombocytopenia). In addition, imatinib has been associated with dyspnea and cough, which are mainly secondary to the pleural effusion and pulmonary edema, which represent local or general fluid retention. These events appear to be dose related and are more common encountered in the elderly. However, there has been no report of hypersensitivity pneumonitis associated with imatinib-mesylate in Korea. We report a case of 51-year old woman who developed hypersensitivity pneumonitis that might have been induced by imatinib-mesylate during the treatment of a gastrointestinal stromal tumor.
Keywords
Imatinib-mesylate; Hypersensitivity pneumonitis; Gastrointestinal stromal tumor;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-6   DOI   ScienceOn
2 Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, et al. Malignant gastrointestinal stromal tumor of small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med 2005;44:114-9   DOI   ScienceOn
3 van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001;358: 1421-3   DOI   ScienceOn
4 Rankin C, von Mehren M, Blanke C. Dose effect of imatinib in patients with metastatic GIST-a phase III sarcoma group study S0033 [Abstract]. Proc Annu Meet Am Soc Clin Oncol 2004:9005
5 Rasado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. imatinib mesylateinduced interstitial pneumonitis. J Clin Oncol 2003; 21:3171-3   DOI   PUBMED